Aardvark Therapeutics (NASDAQ: AARD) secured Institutional Review Board approval for an amended protocol of its Phase 3 HERO trial of ARD‑101, the company’s lead candidate for treating hyperphagia in Prader‑Willi Syndrome (PWS). The amendment lowers the minimum age of eligible participants from 10 to 7 years, broadening the study’s patient population and removing a key enrollment barrier.
The expanded eligibility is expected to accelerate enrollment and improve the representativeness of the trial cohort. By enrolling younger children, Aardvark can capture the full spectrum of disease severity, which should enhance the robustness of efficacy and safety analyses and support a more reliable statistical power assessment. The company anticipates that topline data will be available in the third quarter of 2026, a critical milestone for progressing toward regulatory approval.
ARD‑101 is a gut‑restricted small‑molecule agonist of bitter taste receptors (TAS2Rs) that stimulates the release of satiety hormones such as GLP‑1 and CCK. The drug has received FDA Orphan Drug Designation and Rare Pediatric Disease Designation for PWS, positioning it as a differentiated therapy in a market with no approved treatments. While GLP‑1 agonists dominate the obesity space, ARD‑101’s unique mechanism offers a potential advantage in addressing the chronic hyperphagia that drives obesity in PWS patients.
Aardvark remains a pre‑revenue, clinical‑stage company. As of March 31, 2025, it held $151.3 million in cash, cash equivalents, and short‑term investments, projected to fund operations through 2027. The company raised $94.2 million in its February 2025 IPO, and its current burn rate is consistent with the cash runway, underscoring the importance of timely trial milestones for future funding needs.
CEO Tien Lee said, “Expanding eligibility to include children as young as 7 years of age reflects our commitment to addressing the urgent needs of the PWS community and ensures broad, equitable access to a differentiated therapy.” He added that enrollment is progressing steadily and the company remains on track to report topline data in Q3 2026, which will inform the next steps toward regulatory approval.
Beyond PWS, Aardvark is advancing ARD‑201, a combination of ARD‑101 with a DPP‑4 inhibitor, for obesity and related metabolic conditions. The broader strategy aims to leverage ARD‑101’s gut‑restricted profile across multiple indications, potentially expanding the company’s market reach and reinforcing its position in the metabolic disease space.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.